Discovery
Michigan State wins NIH grant to probe high-risk autism gene ASH1L
Michigan State University has received a USD 1.03 million National Institute of Mental Health RF1 award to investigate how loss-of-function mutations in the...
Texas A&M gets renewed NIH backing for MLL-rearranged leukemia drug discovery
Texas A&M University has received a USD 1.44 million fiscal year 2026 renewal of an NIH R01 grant from the National Cancer Institute to advance a...
Atai Therapeutics wins USD 2.73m NIH grant for non-hallucinogenic psychedelic compounds in opioid disorder
atai Therapeutics has received a USD 2.73 million UG3 cooperative agreement from the National Institute on Drug Abuse to advance non-hallucinogenic...
Emory backed by NIH to push EP2 antagonist for Alzheimer's towards IND
Emory University has received a USD 1.87 million NIH U01 grant to advance an EP2 receptor antagonist toward IND-enabling studies for Alzheimer's disease,...
Sinopia Bio's PKA-II modulator demonstrates dyskinesia reduction in preclinical Parkinson's models
<a...
JAMA: Blood p-tau217 predicts cognitive impairment up to 13.5 years before Alzheimer's symptoms
Researchers at Mass General Brigham in Boston, working with collaborators across six North American cohorts, report that baseline plasma phosphorylated tau...
ARPA-H awards USD 160m to accelerate rare disease gene editing through umbrella clinical trials
ARPA-H has announced up to USD 160 million in funding over five years for seven performer teams under its THRIVE (Treating Hereditary Rare Diseases with In...
Amydis secures USD 1.1m NIH award to develop retinal imaging for TDP-43 detection
Amydis, a La Jolla, California-based diagnostics company, has received a USD 1.1 million NIH R44 Phase II SBIR award from the National Institute on Aging to...
JAX joins Broad-led consortium on USD 34.5 million ARPA-H rare disease gene-editing award
The Jackson Laboratory (JAX), in collaboration with the Broad Institute and partners across 12 institutions, has been selected for an up to USD 34.5 million...
Sparian Biosciences advances non-opioid pain drug toward clinical testing with NIDA support
Sparian Biosciences, a New York-based for-profit company, has received a USD 3.1 million NIDA UG3 grant to advance SBS-147, an oral non-opioid analgesic,...
JCVI receives USD 1.79 million NIAID grant to advance phage therapy toward FDA IND
J. Craig Venter Institute has received a USD 1.79 million NIAID R01 award to advance a five-phage therapeutic cocktail targeting antibiotic-resistant...
Cūrza backed by NIAID award for novel ribosomal inhibitor to combat multidrug-resistant infections
Curza Inc, a Salt Lake City-based antibiotic developer, has received a USD 1 million NIAID SBIR award to advance CZ-02, a novel class of oral antibiotics...
Sanford Burnham Prebys develops single-construct gene therapy to boost cardiac cell reprogramming in heart failure
Sanford Burnham Prebys Medical Discovery Institute, the La Jolla, California-based nonprofit research institute, has received a USD 1.6 million NIH R01...
Talus Bio backed by NCATS for AI platform to unlock transcription factors as drug targets
Talus Bioscience Inc, a Seattle-based drug discovery company, has received a USD 1.03 million SBIR R44 grant from the National Center for Advancing...
Ohio State University develops exosome-based RNA nanotechnology to silence mutant KRAS in mCRC
Ohio State University has received a USD 1.43 million NCI R01 grant to develop an exosome-based RNA nanotechnology platform targeting mutant KRAS in...
The AllSci Brief
Systematic R&D and deal news. Daily.